Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and cetuximab
Celldex announced enrollment has opened in its open-label Phase 2 study of CDX-3379 in combination with cetuximab in patients with cetuximab-refractory, advanced head and neck squamous cell carcinoma. CDX-3379 is a human monoclonal antibody that selectively binds and inhibits activity of ErbB3. November 17, 2017